10:08 ET -- Gilead Sciences is one of the most mentioned companies in the U.S. across all news items in the last 12 hours, according to Factiva data. The biopharmaceutical company struck a $4.3 billion deal to buy CymaBay Therapeutics, expanding its portfolio of liver drugs. Dow Jones & Co. owns Factiva. (colin.kellaher@wsj.com)

(END) Dow Jones Newswires

02-12-24 1024ET